Jupiter Asset Management Ltd. Has $1.11 Million Position in CareDx, Inc. (NASDAQ:CDNA)

Jupiter Asset Management Ltd. boosted its holdings in CareDx, Inc. (NASDAQ:CDNA - Free Report) by 118.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,365 shares of the company's stock after buying an additional 33,847 shares during the period. Jupiter Asset Management Ltd. owned approximately 0.11% of CareDx worth $1,107,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in CareDx by 7.1% in the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after buying an additional 323,554 shares during the period. Bamco Inc. NY lifted its holdings in CareDx by 17.6% in the fourth quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock valued at $47,258,000 after buying an additional 330,627 shares during the period. Fred Alger Management LLC lifted its holdings in CareDx by 7.3% in the fourth quarter. Fred Alger Management LLC now owns 1,613,992 shares of the company's stock valued at $34,556,000 after buying an additional 110,471 shares during the period. Invesco Ltd. lifted its holdings in CareDx by 3.5% in the fourth quarter. Invesco Ltd. now owns 1,514,850 shares of the company's stock valued at $32,433,000 after buying an additional 51,160 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in CareDx by 15.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock valued at $30,663,000 after buying an additional 196,298 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CDNA shares. The Goldman Sachs Group cut their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Craig Hallum cut their target price on shares of CareDx from $40.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, July 18th. HC Wainwright reiterated a "neutral" rating and issued a $25.00 target price on shares of CareDx in a report on Monday, May 5th. Wall Street Zen lowered shares of CareDx from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Stephens reiterated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a report on Monday, May 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, CareDx has an average rating of "Hold" and a consensus price target of $29.33.

Insider Activity at CareDx

In other news, Director Hannah Valantine sold 10,570 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the completion of the sale, the director owned 38,994 shares of the company's stock, valued at $747,125.04. This represents a 21.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William A. Hagstrom sold 19,391 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $19.90, for a total transaction of $385,880.90. Following the sale, the director directly owned 53,979 shares of the company's stock, valued at $1,074,182.10. This represents a 26.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,097 shares of company stock worth $1,955,113 over the last three months. 4.40% of the stock is currently owned by insiders.

CareDx Stock Up 3.1%

Shares of CDNA stock opened at $12.60 on Tuesday. The firm has a fifty day moving average of $17.32 and a 200-day moving average of $18.71. CareDx, Inc. has a 12-month low of $10.96 and a 12-month high of $34.84. The company has a market capitalization of $701.57 million, a price-to-earnings ratio of 10.96 and a beta of 2.22.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.